In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ascendis Pharma A/S

http://www.ascendispharma.com/

Latest From Ascendis Pharma A/S

Keeping Track: After COVID Delays, US FDA Approvals At Last For Daxxify, Rolvedon (But A CRL For Alvotech)

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Finance Watch: Blackstone Closes $1.6bn Fund To Back Commercial-Stage Companies

Public Company Edition: Blackstone Life Sciences Yield will finance approved products, while the firm’s prior fund supports late-stage programs. Also, Coeptis will merge with a SPAC, Bausch + Lomb secured post-IPO debt, and BioXcel revealed a $260m financing and new subsidiary.

Financing Business Strategies

Finance Watch: Public Markets Open Back Up For Biopharma Offerings

Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains. 

Financing Strategy

Ascendis Phase III Data Gives TransCon PTH An Edge In Hypoparathyroidism

The firm plans to submit to the US FDA in the third quarter and with the European Medicines Agency in the fourth quarter based on positive Phase III study results.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Visen Pharmaceuticals
UsernamePublicRestriction

Register